Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8471418 | 1.00 | MTNR1A (0.63) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL31483032 | 0.81 | MTNR1A (0.77) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL13690878 | 0.81 | ALDH1A1 (0.66) | NPC1KMT2AHPGDMEN1HSD17B10 | |
| SCHEMBL6195294 | 0.78 | MTNR1A (1.00) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL7072684 | 0.78 | MTNR1A (0.77) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL2830568 | 0.78 | MTNR1A (0.67) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL20463424 | 0.76 | MTNR1A (0.72) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL7448429 | 0.75 | MTNR1A (0.67) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL3514820 | 0.74 | MTNR1A (0.61) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A | |
| SCHEMBL20456218 | 0.73 | MTNR1A (0.68) | MTNR1AMTNR1BNPC1HSP90AA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-1713822-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1713823-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-11-11 | — | — | EP | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713822-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1713823-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073216-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | MTNR1A 2987/4885MTNR1B 2891/4885NPC1 1412/4885 |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | MTNR1A 3641/4885MTNR1B 3026/4885NPC1 1379/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | MTNR1A 3957/4885MTNR1B 3766/4885NPC1 1518/4885 |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | MTNR1A 3641/4885MTNR1B 3026/4885NPC1 1379/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | MTNR1A 3715/4885MTNR1B 3328/4885NPC1 1311/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | MTNR1A 3641/4885MTNR1B 3026/4885NPC1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.